Literature DB >> 26303816

The effects of (-)-epicatechin on endothelial cells involve the G protein-coupled estrogen receptor (GPER).

Aldo Moreno-Ulloa1, David Mendez-Luna2, Ernesto Beltran-Partida3, Carmen Castillo4, Gustavo Guevara4, Israel Ramirez-Sanchez1, José Correa-Basurto5, Guillermo Ceballos4, Francisco Villarreal6.   

Abstract

We have provided evidence that the stimulatory effects of (-)-epicatechin ((-)-EPI) on endothelial cell nitric oxide (NO) production may involve the participation of a cell-surface receptor. Thus far, such entity(ies) has not been fully elucidated. The G protein-coupled estrogen receptor (GPER) is a cell-surface receptor that has been linked to protective effects on the cardiovascular system and activation of intracellular signaling pathways (including NO production) similar to those reported with (-)-EPI. In bovine coronary artery endothelial cells (BCAEC) by the use of confocal imaging, we evidence the presence of GPER at the cell-surface and on F-actin filaments. Using in silico studies we document the favorable binding mode between (-)-EPI and GPER. Such binding is comparable to that of the GPER agonist, G1. By the use of selective blockers, we demonstrate that the activation of ERK 1/2 and CaMKII by (-)-EPI is dependent on the GPER/c-SRC/EGFR axis mimicking those effects noted with G1. We also evidence by the use of siRNA the role that GPER has on mediating ERK1/2 activation by (-)-EPI. GPER appears to be coupled to a non Gαi/o or Gαs, protein subtype. To extrapolate our findings to an ex vivo model, we employed phenylephrine pre-contracted aortic rings evidencing that (-)-EPI can mediate vasodilation through GPER activation. In conclusion, we provide evidence that suggests the GPER as a potential mediator of (-)-EPI effects and highlights the important role that GPER may have on cardiovascular system protection.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  (−)-Epicatechin; Cacao; Docking; EGFR; ERK 1/2; GPER

Mesh:

Substances:

Year:  2015        PMID: 26303816      PMCID: PMC4555879          DOI: 10.1016/j.phrs.2015.08.014

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  61 in total

Review 1.  G protein-coupled oestrogen receptor 1 (GPER1)/GPR30: a new player in cardiovascular and metabolic oestrogenic signalling.

Authors:  Bengt-Olof Nilsson; Björn Olde; L M Fredrik Leeb-Lundberg
Journal:  Br J Pharmacol       Date:  2011-07       Impact factor: 8.739

2.  Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF.

Authors:  E J Filardo; J A Quinn; K I Bland; A R Frackelton
Journal:  Mol Endocrinol       Date:  2000-10

3.  Two novel GPER agonists induce gene expression changes and growth effects in cancer cells.

Authors:  R Lappano; C Rosano; M F Santolla; M Pupo; E M De Francesco; P De Marco; M Ponassi; A Spallarossa; A Ranise; M Maggiolini
Journal:  Curr Cancer Drug Targets       Date:  2012-06       Impact factor: 3.428

4.  Identification of a GPER/GPR30 antagonist with improved estrogen receptor counterselectivity.

Authors:  Megan K Dennis; Angela S Field; Ritwik Burai; Chinnasamy Ramesh; Whitney K Petrie; Cristian G Bologa; Tudor I Oprea; Yuri Yamaguchi; Shin-Ichi Hayashi; Larry A Sklar; Helen J Hathaway; Jeffrey B Arterburn; Eric R Prossnitz
Journal:  J Steroid Biochem Mol Biol       Date:  2011-07-14       Impact factor: 4.292

5.  Estrogen action via the G protein-coupled receptor, GPR30: stimulation of adenylyl cyclase and cAMP-mediated attenuation of the epidermal growth factor receptor-to-MAPK signaling axis.

Authors:  Edward J Filardo; Jeffrey A Quinn; A Raymond Frackelton; Kirby I Bland
Journal:  Mol Endocrinol       Date:  2002-01

6.  Improvement of vascular function by acute and chronic treatment with the GPR30 agonist G1 in experimental diabetes mellitus.

Authors:  Zi-lin Li; Jin-cheng Liu; Shui-bing Liu; Xiao-qiang Li; Ding-hua Yi; Ming-gao Zhao
Journal:  PLoS One       Date:  2012-06-05       Impact factor: 3.240

7.  MIBE acts as antagonist ligand of both estrogen receptor α and GPER in breast cancer cells.

Authors:  Rosamaria Lappano; Maria Francesca Santolla; Marco Pupo; Maria Stefania Sinicropi; Anna Caruso; Camillo Rosano; Marcello Maggiolini
Journal:  Breast Cancer Res       Date:  2012-01-17       Impact factor: 6.466

Review 8.  Chocolate consumption and cardiometabolic disorders: systematic review and meta-analysis.

Authors:  Adriana Buitrago-Lopez; Jean Sanderson; Laura Johnson; Samantha Warnakula; Angela Wood; Emanuele Di Angelantonio; Oscar H Franco
Journal:  BMJ       Date:  2011-08-26

Review 9.  Molecular dynamics simulations and drug discovery.

Authors:  Jacob D Durrant; J Andrew McCammon
Journal:  BMC Biol       Date:  2011-10-28       Impact factor: 7.431

10.  A calixpyrrole derivative acts as an antagonist to GPER, a G-protein coupled receptor: mechanisms and models.

Authors:  Rosamaria Lappano; Camillo Rosano; Assunta Pisano; Maria Francesca Santolla; Ernestina Marianna De Francesco; Paola De Marco; Vincenza Dolce; Marco Ponassi; Lamberto Felli; Grazia Cafeo; Franz Heinrich Kohnke; Sergio Abonante; Marcello Maggiolini
Journal:  Dis Model Mech       Date:  2015-07-16       Impact factor: 5.758

View more
  25 in total

1.  A pilot study on clinical pharmacokinetics and preclinical pharmacodynamics of (+)-epicatechin on cardiometabolic endpoints.

Authors:  Aldo Moreno-Ulloa; Nayelli Nájera-García; Marcela Hernández; Israel Ramírez-Sánchez; Pam R Taub; Yongxuan Su; Ernesto Beltrán-Partida; Guillermo Ceballos; Sundeep Dugar; George Schreiner; Brookie M Best; Theodore P Ciaraldi; Robert R Henry; Francisco Villarreal
Journal:  Food Funct       Date:  2018-01-24       Impact factor: 5.396

2.  Dark Chocolate Supplementation Elevates Resting Energy Expenditure in Exercise Trained Females.

Authors:  Katie M Presler; Michael J Webster
Journal:  Int J Exerc Sci       Date:  2021-04-01

3.  (-)-Epicatechin stimulates mitochondrial biogenesis and cell growth in C2C12 myotubes via the G-protein coupled estrogen receptor.

Authors:  Aldo Moreno-Ulloa; Adriana Miranda-Cervantes; Alexei Licea-Navarro; Christina Mansour; Ernesto Beltrán-Partida; Luis Donis-Maturano; Hilda C Delgado De la Herrán; Francisco Villarreal; Carolina Álvarez-Delgado
Journal:  Eur J Pharmacol       Date:  2018-01-20       Impact factor: 4.432

4.  A novel GPER antagonist protects against the formation of estrogen-induced cholesterol gallstones in female mice.

Authors:  Chelsea DeLeon; Helen H Wang; Joseph Gunn; McKenna Wilhelm; Aidan Cole; Stacy Arnett; David Q-H Wang; Christopher K Arnatt
Journal:  J Lipid Res       Date:  2020-03-03       Impact factor: 5.922

5.  Synthesis of novel (-)-epicatechin derivatives as potential endothelial GPER agonists: Evaluation of biological effects.

Authors:  Viviana Sarmiento; Israel Ramirez-Sanchez; Aldo Moreno-Ulloa; Diego Romero-Perez; Daniel Chávez; Miguel Ortiz; Nayelli Najera; Jose Correa-Basurto; Francisco Villarreal; Guillermo Ceballos
Journal:  Bioorg Med Chem Lett       Date:  2018-01-24       Impact factor: 2.823

6.  Effects of Cacao By-Products and a Modest Weight Loss Intervention on the Concentration of Serum Triglycerides in Overweight Subjects: Proof of Concept.

Authors:  Perla León-Flores; Nayelli Nájera; Elizabeth Pérez; Blanca Pardo; Fiacro Jimenez; Dylan Diaz-Chiguer; Francisco Villarreal; Isabel Hidalgo; Guillermo Ceballos; Eduardo Meaney
Journal:  J Med Food       Date:  2020-04-15       Impact factor: 2.786

7.  Beneficial effects of dark chocolate on exercise capacity in sedentary subjects: underlying mechanisms. A double blind, randomized, placebo controlled trial.

Authors:  Pam R Taub; Israel Ramirez-Sanchez; Minal Patel; Erin Higginbotham; Aldo Moreno-Ulloa; Luis Miguel Román-Pintos; Paul Phillips; Guy Perkins; Guillermo Ceballos; Francisco Villarreal
Journal:  Food Funct       Date:  2016-08-05       Impact factor: 5.396

8.  Epicatechin potentiation of glucose-stimulated insulin secretion in INS-1 cells is not dependent on its antioxidant activity.

Authors:  Kaiyuan Yang; Catherine B Chan
Journal:  Acta Pharmacol Sin       Date:  2018-02-01       Impact factor: 6.150

9.  Effects of Cocoa-Derived Polyphenols on Cognitive Function in Humans. Systematic Review and Analysis of Methodological Aspects.

Authors:  Paloma K Barrera-Reyes; Josué Cortés-Fernández de Lara; Melissa González-Soto; M Elizabeth Tejero
Journal:  Plant Foods Hum Nutr       Date:  2020-03       Impact factor: 3.921

Review 10.  Flavonoids: structure-function and mechanisms of action and opportunities for drug development.

Authors:  Stephen Safe; Arul Jayaraman; Robert S Chapkin; Marcell Howard; Kumaravel Mohankumar; Rupesh Shrestha
Journal:  Toxicol Res       Date:  2021-01-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.